Aeterna Zentaris Inc. (AEZS) stock soared 8.58% in the pre-market trading session at the price of $0.39 despite no recent updates. AEZS is a specialty biopharmaceutical firm that develops and commercializes pharmaceutical products to satisfy unmet medical needs. Macrilen, the company’s lead product, is the first and only FDA-approved oral test to diagnose adult growth hormone deficiency.
Appointment of Giuliano La Fratta
On 23rd December 2021, AEZS appointed Giuliano La Fratta as its Senior Vice President, Chief Financial Officer. The appointment will become effective from 24th January 2022. La Fratta, who succeeded Ms. Leslie Auld, will lead the finance-related leadership operations.
Mr. La Fratta is a financial expert with 20 years of experience in the biopharma, pharmaceutical, and financial services sectors. Before joining AEZS, he has served at CellCarta as Vice President of Finance. Before this role, he has worked in various positions at IMS Canada Health and Cato Research. Mr. La Fratta did his bachelor’s in accounting from Concordia University.
Chief Executive Officer of AEZS, Dr. Klaus Paulini, remarked that they are excited to welcome Mr. La Fratta as the new Chief Financial Officer. His supervision, leadership, and experience will be invaluable to executing the company’s strategic goals. He also thanked Leslie for her relentless devotion and valuable services.
Mr. La Fratta added that AEZS is in its transformational phase. The team has performed exceptional work supporting the financial position of the company. There are substantial opportunities ahead that Aeterna has to address. He looks onward to working with the management team to capitalize on future opportunities.
AEZS Third Quarter 2021 Financial Results
On 4th November 2021, AEZS announced its financial and operating results for the Q3 ended 30th September 2021. The company has also presented updates on its pre-clinical and clinical programs.
The revenue totaled $0.6M for the quarter ended 30th September 2021. For the same quarter of 2020, revenue was $0.1M. The company reported a net loss of $1.7M, or per share of $0.01, for the Q3 of 2021. Net loss was $1.1M, or per share of $0.02, for the quarter ended 30th September 2020.